Vaccines Archives

News and Trends 25 Jun 2015

BioNTech and Siemens to build a new Production plant for Personalized Cancer Vaccines

Personalized medicine is the next thing and immunotherapy expert BioNTech is determined to build its place in this competitive field. With this purpose in mind, the German biotech will partner with Siemens to build a new production plant for personalized cancer vaccines. Founded in 2008, the BioNTech Group has become one of the fastest-growing biotechnology […]

June 25, 2015 - 1 minutemin - By Lourdes Riquelme

News and Trends 25 May 2015

Invectys focuses on Telomers to develop a Universal Cancer Vaccine

French startup Invectys believes to have found the solution to cancer: one vaccine to cure them all! By targeting telomerase, this new immunotherapy could theoretically fight 95 % of all human cancers. When a cell divides, a small piece of DNA, called telomere, is lost at both ends of each chromosome. Telomerase adds these pieces of DNA again at the end of […]

May 25, 2015 - 3 minutesmins - By Joachim Eeckhout

News and Trends 13 May 2015

Sanofi and Selecta will develop a “Negative Vaccine” for Celiac Disease

Sanofi and Selecta Biosciences are going to extend their three-year-old partnership to develop an immunotherapy for the treatment of celiac disease. Selecta may receive €264M from the biggest French Pharma company, in terms of research support and sales milestones. The two companies are now collaborating on three programs for immune tolerance. In celiac disease patients, […]

May 13, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 22 Apr 2015

Vaccines against Parasites, on the Horizon with XstalBio

XstalBio has commenced work on an €9.3M EU Funded Horizon 2020 project to develop vaccines that protect cattle, sheep and poultry, against infection by parasites. The 4 year “PARAGONE” collaboration involves 17 partners from Europe, Uruguay and China and will aim to move several candidate vaccines from the laboratory into practical field trials. XstalBio, as […]

April 22, 2015 - 2 minutesmins - By Lourdes Riquelme

final sterilization proteins solution sanofi pasteur

News and Trends 16 Apr 2015

The challenge of terminal sterilization of Proteins

The production of biologicals is an important challenge for the industry. Today, very often, the only way to have a sterile final product is to, first, use sterile components and then, launch the production in a fully aseptic manufacturing facility. What if we could terminally sterilize the protein-based outcome once produced? More and more biologicals are brought to the market, […]

April 16, 2015 - 3 minutesmins - By Philip Hemme

News and Trends 23 Mar 2015

A Vaccine against Placental Malaria made with ExpreS2ion’s Protein Expression Technology

University of Copenhagen released a vaccine candidate against the form of malaria that strikes pregnant women, for testing in humans. The vaccine candidate contains a malaria antigen made with ExpreS2ion Biotechnologies’ protein expression technology, ExpreS2. This vaccine candidate results from many years of research done by Professor Ali Salanti and his team at the Department […]

March 23, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 22 Feb 2015

Theravectys: an Orphan Drug Designation for Its Lentiviral Vector-Based Therapeutic Vaccine

THERAVECTYS, a fully-integrated discovery and clinical development biotechnology company focusing on the development of therapeutic vaccines and immunotherapy, announced that the European Medicines Agency (EMA) has granted Orphan Drug Designation to its therapeutic vaccine candidate for the treatment of Adult T-cell Leukemia/Lymphoma (ATL/L). ATL/L is a rare malignancy of a certain type of white cells, T-Lymphocytes, caused by the Human T-Cell Lymphotropic Virus type […]

February 22, 2015 - 3 minutesmins - By Joachim Eeckhout

News and Trends 14 Feb 2015

GlycoVaxyn: A new Gain for GSK’s Vaccines Business

GSK, who was already a minority shareholder in GlycoVaxyn, acquires the company and its biological conjugation platform which may help it to develop a new generation of prophylactic vaccines against bacterial infections. GSK has today paid €167M to purchase the remaining stake in the company. GlycoVaxyn’s innovative biological conjugation platform originates enables the development of […]

February 14, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 31 Jan 2015

An Anglo-French Partnership To Cure Hepatitis B

European biotechnology company Valneva and UK company Immune Targeting Systems (ITS) announced that they have signed an exclusive worldwide commercial license agreement. This deal grants ITS the rights to research, develop and commercialize Hepatitis B vaccine candidates in combination with Valneva’s IC31 Adjuvant. Valneva’s IC31 Adjuvant is a unique synthetic adjuvant combining the immuno-stimulating properties […]

January 31, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 7 Dec 2014

Ebola, the fever falls

This article provides an update of the 2014 Ebola outbreak relating to other past outbreaks of this disease. It provides demographic and economic insights into both the disease and the regions affected. It highlights lessons learnt and those that need to be learned. Which sectors are most impacted by this outbreak, and what is the […]

December 7, 2014 - 15 minutesmins - By Cédric Brock

News and Trends 3 Dec 2014

New Technologies Against Allergies are on the Wave

Anergis, a company developing proprietary ultra-fast allergy vaccines, closed a Series B financing round totaling 12,1 million euros. Anergis is not the only company that focuses on allergies, DBV technologies also recently raised money for its new anti-allergic patch. Allergies are the most prevalent and fastest growing chronic conditions in the industrialized world affecting over 500 million […]

December 3, 2014 - 2 minutesmins - By Julie Lellouche

CSL pays 275m to acquire Novartis flu vaccines manufacturing sites strict xxl

News and Trends 31 Oct 2014

Novartis steps down completely from Vaccines’ Business

Novartis divests its influenza vaccines business to CSL Limited, an Australian company, for an agreed price of 219 million euros, completing the last deal with GSK a few months ago. This is a strategic move of Novartis; they plan to focus on the pharmaceutical business, ophthalmology (Alcon) and generics (Sandoz). Last year, influenza vaccine business reached a turnover of 1 […]

October 31, 2014 - 2 minutesmins - By Julie Lellouche

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Vaccines

BioNTech and Siemens to build a new Production plant for Personalized Cancer Vaccines

Invectys focuses on Telomers to develop a Universal Cancer Vaccine

Sanofi and Selecta will develop a “Negative Vaccine” for Celiac Disease

Vaccines against Parasites, on the Horizon with XstalBio

The challenge of terminal sterilization of Proteins

A Vaccine against Placental Malaria made with ExpreS2ion’s Protein Expression Technology

Theravectys: an Orphan Drug Designation for Its Lentiviral Vector-Based Therapeutic Vaccine

GlycoVaxyn: A new Gain for GSK’s Vaccines Business

An Anglo-French Partnership To Cure Hepatitis B

Ebola, the fever falls

New Technologies Against Allergies are on the Wave

Novartis steps down completely from Vaccines’ Business

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!